Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia Alnylam Pharmaceuticals cialis reviews.

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia Alnylam Pharmaceuticals, Inc cialis reviews . , a leading RNAi therapeutics company, announced today that it provides initiated dosing in its Phase I medical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia. The study is aimed at evaluating the protection and tolerability of ALN-PCS in subjects with elevated low-density lipoprotein cholesterol . Furthermore, the analysis will evaluate scientific activity of ALN-PCS based on measurements of plasma PCSK9 proteins and serum LDLc levels.

Rebecca Simmons, Noreen Maconochie and Pat Doyle from the London College of Hygiene and Tropical Medicine found that Gulf war veterans were more likely to record mood swings, memory loss/lack of concentration, night time sweats, general fatigue and sexual dysfunction than military personnel who hadn’t served in the Gulf. This pattern of symptom reporting is similar to that found in other research of UK Gulf war veterans, which looked at the same population using different methods. The analysis confirmed that Gulf battle veterans report significantly more symptoms of disease than non-Gulf battle veterans in almost all ill health classes examined, yet there is no consistent explanation because of this discrepancy still.